What Is Sculptra? The Approval Record, the Trials and the Reports Behind a Collagen Stimulator

Sculptra sits on the menu of almost every aesthetic clinic, usually under the heading "collagen stimulator", and the question most people type first is simply what it is. The short answer is a US-approved injectable device made of poly-L-lactic acid. The longer answer — what it was approved for, what the trials measured, and what reports have been filed about it — is all in public records, and this page reads them. It does not recommend any treatment. Whether an injectable is appropriate is a medical decision for a qualified clinician, and nothing here is a treatment plan.

What Sculptra is

Sculptra is poly-L-lactic acid (PLLA), a synthetic polymer of lactic acid that the body breaks down slowly. It is supplied as a dry powder in a vial and mixed with sterile water before it is injected into the deep layer of the skin. The pivotal cheek-wrinkle trial describes the dose as one vial containing 150 mg of PLLA, reconstituted in 8 mL of sterile water with 1 mL of lidocaine added (Fabi 2024).

Two things it is not. It is not hyaluronic acid, the material in most fillers and in SKINVIVE, which our skin boosters page covers and our reading of the SKINVIVE approval file sets out in detail. And it is not a peptide, despite sharing clinic menus and social feeds with peptide and DNA-based "boosters" such as PDRN.

The approval record, dated

Sculptra is regulated in the US as a medical device through premarket approval, the strictest device pathway. FDA's approval database, read on 30 September 2026, holds 54 records under PMA number P030050: the original approval and 53 supplements. Most supplements concern manufacturing — sterilisation sites, autoclaves, milling batch sizes. A handful changed what the device is for or how it is labelled:

The order matters for reading any claim about Sculptra. It began as a reconstructive device for a specific medical problem — the facial fat loss caused by early HIV drugs — and reached cosmetic use five years later. Every approved indication is on the face. Uses elsewhere on the body appear in published studies but are not among the approved indications in this record. Off-label body use, including the buttocks, has its own small literature and its own FDA reports, set out in the record on Sculptra for the buttocks.

Where the "collagen stimulator" label comes from

A hyaluronic-acid filler works mostly by occupying space: the gel is the volume. PLLA is described differently. The particles are placed in the deep dermis, and the tissue response around them — including new collagen — is credited with the gradual change in contour. That is why Sculptra is grouped with calcium hydroxylapatite (Radiesse) and polycaprolactone (Ellansé) under the name biostimulators, and why its trials read results months after the last session rather than on the day. How this compares with the other main stimulator, calcium hydroxylapatite, is laid out in Sculptra vs Radiesse.

Two recent randomized studies by Waibel and colleagues compared gene activity in skin after PLLA and after calcium hydroxylapatite (Waibel 2024; Waibel 2025) and describe the two materials as working through different tissue responses. Those are mechanism studies of small groups, not outcome trials, and they are best read as evidence that the two products are not interchangeable rather than as a ranking of either.

What the trials measured

A PubMed search on 30 September 2026 for poly-L-lactic acid or Sculptra together with face, wrinkles, lipoatrophy or aesthetic use returned 615 records, 36 of them tagged as randomized controlled trials. Reading the 36 one by one, three are about bioresorbable plates in jaw surgery — PLLA is also a surgical material — and several test PLLA on the body (thighs, buttocks, knees, décolletage), outside the approved indications. The retracted-publication filter returned no retracted Sculptra trial; the four retracted PLLA records are a skin-booster review, a surgical nanofibre paper, a different filler and a drug nanoparticle study.

The trials behind the three approvals, in order:

• HIV lipoatrophy. An open-label study randomized 30 people with HIV to immediate or delayed injections of the European forerunner product, New-Fill; the immediate group reported better self-perception at week 12, and the authors report benefits persisting at least 18 weeks after the last injection (Moyle 2004). A longer study followed patients for 48 weeks (Carey 2009).
• Nasolabial folds. The trial that supported Sculptra Aesthetic randomized 116 people to PLLA and 117 to human-derived collagen, one to four sessions three weeks apart, evaluator-blinded. PLLA scored better than collagen from month 3 to month 13, and the PLLA group was followed to 25 months (Narins 2010). Its authors name its main limitation themselves: participants were mostly white women with Fitzpatrick skin types II and III.
• Cheek wrinkles. The 2023 approval rests on a trial that randomized adults 2:1 to PLLA or no treatment, with up to four sessions a month apart (Fabi 2024; registry NCT04124692, sponsor Galderma, 149 enrolled). The share of people improving by at least one grade on the sponsor's cheek-wrinkle scale:

Two features of that table are easy to miss. The comparison is against no treatment, not against another filler or a sham injection, so it answers "better than nothing?" rather than "better than the alternatives?". And a quarter to a third of the untreated group also improved by a grade — the scale is graded by eye, and that is the size of the background movement on it.

Sessions, as the trials describe them

The trials describe a series rather than a single appointment: one to four sessions in the nasolabial-fold trial, three weeks apart; up to four, a month apart, in the cheek trial. This is reported as the design of those studies. How many sessions any individual receives is decided by the treating clinician and is outside what this page covers. What the record does show is that the preparation itself has changed over time: a randomized study tested a larger dilution volume used immediately after mixing (Palm 2021), and FDA approved a changed reconstitution procedure in November 2021.

Lumps, nodules and what was reported to FDA

The complication most associated with PLLA in the literature is the nodule — a lump under the skin, sometimes appearing months after treatment. A PubMed search on 30 September 2026 for PLLA or Sculptra with nodules, papules or granulomas returned 161 records.

One widely repeated piece of aftercare advice has been tested. The "5-5-5" rule — massage the area five times a day, for five minutes, for five days — was put to a randomized, evaluator-blinded trial of 20 people with facial fat loss. Neither the massage group nor the no-massage group developed nodules, and results did not differ between them (Wu and Goldman 2016). Twenty people is small, and a trial that sees no nodules at all cannot say much about how often they occur; it does show the rule was an assumption before it was a finding.

FDA's device-report database, MAUDE, held 2,023 reports naming Sculptra on 30 September 2026, against 1,660 naming Radiesse (a comparison of volume only; neither figure is a rate, because nobody knows how many treatments each represents). The patient problems most often coded:

924 of the 2,023 reports were received in 2009, the year of the cosmetic approval; the database does not say why, and a single-year spike of that size usually reflects how reports were filed rather than a change in the product. From 2013 onward the count has run between 8 and 68 a year. A MAUDE report is an allegation, not a finding: it may be incomplete, duplicated or unrelated to the device.

In the cheek-wrinkle trial's posted results, 3 of 97 treated participants had a serious adverse event (0 of 52 untreated) and 11 of 97 had injection-site bruising; the published paper states that no serious event was judged related to the injections. In 2023 FDA approved labelling that adds delayed-onset inflammation at filler injection sites after viral or bacterial illness, infection or vaccination.

What the record does not show

• No head-to-head trial against a hyaluronic-acid filler supported a US approval. The approval trials used human collagen (2009) and no treatment (2023) as comparators. A randomized, evaluator-blinded comparison with hyaluronic acid for nasolabial folds was published in 2015 (Hyun 2015), outside the approval file.
• No approved use off the face. Body studies exist; FDA's indications are facial.
• Limited data across skin types. The nasolabial-fold trial names its narrow population; the record does not contain an equivalent approval trial in darker skin types.
• No product ranking here. This page reports what is on record about one device. It does not say whether Sculptra is a good choice for anyone, and it does not compare it favourably or unfavourably with any other product.

Related reading: the skin boosters page sorts injectables by material; polynucleotides for skin and PDRN cover the DNA-based injectables sold alongside Sculptra; peptides for loose skin covers what topical products can and cannot claim for laxity.

Sources

• US FDA, Premarket Approval database, PMA P030050 and supplements S001–S056 (Sculptra / Sculptra Aesthetic), via openFDA device PMA endpoint, read 2026-09-30.
• US FDA, MAUDE device adverse-event reports, brand name Sculptra (2,023) and Radiesse (1,660), via openFDA device event endpoint, counts by patient problem and by year received, read 2026-09-30.
• ClinicalTrials.gov, NCT04124692, Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles (Galderma R&D), posted results and adverse-event tables, read 2026-09-30.
• Fabi S, et al. Effectiveness and Safety of Sculptra Poly-L-Lactic Acid Injectable Implant in the Correction of Cheek Wrinkles. J Drugs Dermatol 2024;23(1):1297-1305 — PMID 38206151.
• Narins RS, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol 2010;62(3):448-62 — PMID 20159311.
• Moyle GJ, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004;5(2):82-7 — PMID 15012646.
• Carey D, et al. Poly-L-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up. HIV Med 2009 — PMID 19245538.
• Wu DC, Goldman MP. The Efficacy of Massage in Reducing Nodule Formation After Poly-L-Lactic Acid Administration for Facial Volume Loss. Dermatol Surg 2016;42(11):1266-72 — PMID 27618389.
• Palm M, et al. A Randomized Study on PLLA Using Higher Dilution Volume and Immediate Use Following Reconstitution. J Drugs Dermatol 2021 — PMID 34232000.
• Waibel J, et al. (2024) PMID 39480040 and (2025) PMID 39761144 — gene-expression comparisons of PLLA and calcium hydroxylapatite.
• Hyun MY, et al. Efficacy and safety of injection with poly-L-lactic acid compared with hyaluronic acid for correction of nasolabial fold: a randomized, evaluator-blinded, comparative study. Clin Exp Dermatol 2015 — PMID 25319932.
• PubMed counts via NCBI E-utilities, run 2026-09-30, each checked for unmatched phrases; RCT filter "randomized controlled trial"[pt] and "Retracted Publication"[pt].